Cargando…
Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials
Despite appealing characteristics for the clinical trials setting, Bayesian inference methods remain scarcely used, especially in randomized controlled clinical trials (RCT). This is particularly true when dealing with a survival endpoint, likely due to the additional complexities to model specifica...
Autores principales: | Biard, Lucie, Bergeron, Anne, Lévy, Vincent, Chevret, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817368/ https://www.ncbi.nlm.nih.gov/pubmed/33511301 http://dx.doi.org/10.1016/j.conctc.2021.100709 |
Ejemplares similares
-
Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression
por: Andrillon, Anaïs, et al.
Publicado: (2022) -
Challenges of using external data in clinical trials- an illustration in patients with COVID-19
por: Chevret, Sylvie, et al.
Publicado: (2022) -
Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome
por: Vinnat, Valentin, et al.
Publicado: (2022) -
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials – an example in hemato-oncology
por: Jacob, Louis, et al.
Publicado: (2016) -
Simulation study for evaluating an adaptive-randomisation Bayesian hybrid trial design with enrichment
por: Vinnat, Valentin, et al.
Publicado: (2023)